| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:37031830 | IVR | 0.00001 mg/L | 0.00001 mg/L | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 0.00001 mg/L | 0.00001 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/L | 0.00001 mg/L | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/L | 0.00001 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00001 mg/L | 0.00001 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| PMID:37523981 | IVR | 1 mg/kg | 1 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Cognitive impairment | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.